Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
Primary Purpose
Plasmodium Infections
Status
Completed
Phase
Phase 3
Locations
Sudan
Study Type
Interventional
Intervention
sulfadoxine-pyrimethamine (SP) plus artesunate (AS)
primaquine (PQ) plus SP+AS
Sponsored by
About this trial
This is an interventional treatment trial for Plasmodium Infections focused on measuring malaria, subpatent parasitaemia, dry season, primaquine, Plasmodium falciparum infection detected by PCR
Eligibility Criteria
Inclusion Criteria: infection with P.falciparum detected by PCR Exclusion Criteria: pregnancy severe anaemia fever or other signs of illness history of allergy to sulfa drugs presence of other species of Plasmodium detected by microscopy
Sites / Locations
- Tropical Medicine Research Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
1
2
Arm Description
Sulfadoxine pyrimethamine plus three daily doses of artesunate
Sulfadoxine pyrimethamine plus artesunate plus primaquine
Outcomes
Primary Outcome Measures
P.falciparum parasitaemia detected by PCR on days 3,7 and 14.
Secondary Outcome Measures
Presence of gametocytes detected by RT-PCR on days 3, 7 and 14.
Packed Cell volume on days 7 and 14.
Full Information
NCT ID
NCT00330902
First Posted
May 25, 2006
Last Updated
October 30, 2007
Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Tropical Medicine Research Institute, World Health Organization
1. Study Identification
Unique Protocol Identification Number
NCT00330902
Brief Title
Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
Official Title
Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan
Study Type
Interventional
2. Study Status
Record Verification Date
October 2007
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Tropical Medicine Research Institute, World Health Organization
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short transmission season. We did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season.
Detailed Description
104 individuals with low density Plasmodium falciparum infection detected by polymerase chain reaction (PCR) were randomized to receive sulfadoxine-pyrimethamine and three daily doses of artesunate (SP+AS) or SP+AS and a dose of primaquine (SP+AS+PQ), and were followed up for 14 days during the transmission-free season in Eastern Sudan. Subjects were visited on days 3, 7 and 14 after the start of treatment to record any adverse events and to detect P.falciparum using PCR. PCR positive samples were tested for gametocytes using RT-PCR. Packed cell volume was measured on days 7 and 14.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plasmodium Infections
Keywords
malaria, subpatent parasitaemia, dry season, primaquine, Plasmodium falciparum infection detected by PCR
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
104 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Sulfadoxine pyrimethamine plus three daily doses of artesunate
Arm Title
2
Arm Type
Experimental
Arm Description
Sulfadoxine pyrimethamine plus artesunate plus primaquine
Intervention Type
Drug
Intervention Name(s)
sulfadoxine-pyrimethamine (SP) plus artesunate (AS)
Intervention Description
sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
Intervention Type
Drug
Intervention Name(s)
primaquine (PQ) plus SP+AS
Intervention Description
single dose of primaquine on day 4
Primary Outcome Measure Information:
Title
P.falciparum parasitaemia detected by PCR on days 3,7 and 14.
Time Frame
14 days from start of treatment
Secondary Outcome Measure Information:
Title
Presence of gametocytes detected by RT-PCR on days 3, 7 and 14.
Time Frame
14 days from start of treatment
Title
Packed Cell volume on days 7 and 14.
Time Frame
Over 14 days from start of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
infection with P.falciparum detected by PCR
Exclusion Criteria:
pregnancy
severe anaemia
fever or other signs of illness
history of allergy to sulfa drugs
presence of other species of Plasmodium detected by microscopy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Badria B El Sayed, PhD
Organizational Affiliation
TMRI, Khartoum
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Omer Z Baraka, MD
Organizational Affiliation
Faculty of Medicine, University of Khartoum
Official's Role
Study Chair
Facility Information:
Facility Name
Tropical Medicine Research Institute
City
Khartoum
Country
Sudan
12. IPD Sharing Statement
Citations:
PubMed Identifier
18074034
Citation
El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One. 2007 Dec 12;2(12):e1311. doi: 10.1371/journal.pone.0001311.
Results Reference
derived
Learn more about this trial
Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
We'll reach out to this number within 24 hrs